Back to Newsroom

Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone)

BETHESDA, Maryland and ABINGDON, Oxfordshire, July 23, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the United Kingdom’sNational Institute of Health and Care Excellence (NICE) has published the technology appraisal guidance recommending the use of AMITIZA® (lubiprostone) in the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults who have failed laxatives.

Click here to read more